Management of a case of neuroleptic malignant syndrome with bromocriptine.
Neuroleptic malignant syndrome, a rare but potentially fatal side effect of antipsychotic medications, has often proven refractory to conventional antiparkinsonian medications. The authors report a dramatic response of this syndrome to the dopamine agonist bromocriptine mesylate in a patient receiving fluphenazine decanoate.
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001342:Autonomic Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use*; D005334:Fever / Q000139:chemically induced* / Q000188:drug therapy; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D009127:Muscle Rigidity / Q000139:chemically induced / Q000188:drug therapy
D000978:Antiparkinson Agents; D001971:Bromocriptine; C011825:fluphenazine depot; D005476:Fluphenazine